Ying‐Jun Chang

7.3k total citations
278 papers, 4.8k citations indexed

About

Ying‐Jun Chang is a scholar working on Hematology, Immunology and Oncology. According to data from OpenAlex, Ying‐Jun Chang has authored 278 papers receiving a total of 4.8k indexed citations (citations by other indexed papers that have themselves been cited), including 221 papers in Hematology, 122 papers in Immunology and 67 papers in Oncology. Recurrent topics in Ying‐Jun Chang's work include Hematopoietic Stem Cell Transplantation (170 papers), Acute Myeloid Leukemia Research (92 papers) and Immune Cell Function and Interaction (81 papers). Ying‐Jun Chang is often cited by papers focused on Hematopoietic Stem Cell Transplantation (170 papers), Acute Myeloid Leukemia Research (92 papers) and Immune Cell Function and Interaction (81 papers). Ying‐Jun Chang collaborates with scholars based in China, United States and Japan. Ying‐Jun Chang's co-authors include Xiao‐Jun Huang, Lan‐Ping Xu, Kai‐Yan Liu, Yu Wang, Xiaohui Zhang, Xiaosu Zhao, Yu‐Hong Chen, Huan Chen, Xiao‐Dong Mo and Feng‐Rong Wang and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ying‐Jun Chang

261 papers receiving 4.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ying‐Jun Chang China	38	3.4k	2.0k	1.2k	779	618	278	4.8k
Guido Kobbe Germany	40	3.8k 1.1×	961 0.5×	1.3k 1.1×	1.0k 1.3×	281 0.5×	204	5.2k
A Eldor Israel	17	3.1k 0.9×	1.2k 0.6×	913 0.8×	572 0.7×	273 0.4×	40	3.8k
David Valcárcel Spain	32	2.0k 0.6×	578 0.3×	700 0.6×	427 0.5×	272 0.4×	157	2.9k
Carmella van de Ven United States	31	1.1k 0.3×	1.1k 0.5×	891 0.7×	503 0.6×	537 0.9×	151	2.9k
John M. McCarty United States	23	1.8k 0.5×	856 0.4×	983 0.8×	303 0.4×	252 0.4×	70	3.6k
Makoto Onizuka Japan	24	1.5k 0.4×	853 0.4×	445 0.4×	467 0.6×	221 0.4×	201	2.4k
Jack Bleesing United States	35	1.8k 0.5×	2.7k 1.4×	543 0.4×	148 0.2×	285 0.5×	108	4.0k
Meinolf Suttorp Germany	32	2.6k 0.7×	951 0.5×	944 0.8×	752 1.0×	129 0.2×	184	4.0k
K Lilleby United States	24	2.8k 0.8×	840 0.4×	1.6k 1.3×	290 0.4×	215 0.3×	38	3.7k
Michele Falda Italy	25	1.8k 0.5×	660 0.3×	551 0.5×	482 0.6×	332 0.5×	55	3.6k

Countries citing papers authored by Ying‐Jun Chang

Since Specialization

Citations

This map shows the geographic impact of Ying‐Jun Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying‐Jun Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying‐Jun Chang more than expected).

Fields of papers citing papers by Ying‐Jun Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying‐Jun Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying‐Jun Chang. The network helps show where Ying‐Jun Chang may publish in the future.

Co-authorship network of co-authors of Ying‐Jun Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Ying‐Jun Chang. A scholar is included among the top collaborators of Ying‐Jun Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying‐Jun Chang. Ying‐Jun Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wang, H., et al.. (2025). Recent Advances in nccRCC Classification and Therapeutic Approaches. Cells. 14(22). 1781–1781.

Wu, Lixin, Lixia Liu, Shanbo Cao, et al.. (2025). Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia. British Journal of Haematology. 208(1). 170–178.

Zhao, Zihao, et al.. (2025). Multi‐omics integration analysis identifies INPP4B as a T‐cell‐specific activation suppressor. Clinical and Translational Medicine. 15(8). e70430–e70430. 1 indexed citations

Wang, Jing, Siqi Li, Ying‐Jun Chang, et al.. (2024). Sintilimab plus decitabine for higher-risk treatment-naïve myelodysplastic syndromes: efficacy, safety, and biomarker analysis of a phase II, single-arm trial. Journal for ImmunoTherapy of Cancer. 12(11). e010355–e010355. 3 indexed citations

Zhang, Yuanyuan, Yazhe Wang, Ya‐Zhen Qin, et al.. (2024). Cytology or Multiparameter Flow Cytometry Positivity in the Cerebrospinal Fluid Before Transplantation is Predictive of Poor Outcomes After Allotransplantation in Acute Myeloid Leukemia Patients. Clinical Transplantation. 38(7). e15396–e15396.

Zhou, Jianying, Xiaolu Zhu, Yun He, et al.. (2024). A prognostic score system in adult T‐cell acute lymphoblastic leukemia after hematopoietic stem cell transplantation. Bone Marrow Transplantation. 59(4). 496–504. 2 indexed citations

Zhao, Weijia, Yujia Wang, Xinwei Zhang, et al.. (2023). Impaired thymic iNKT cell differentiation at early precursor stage in murine haploidentical bone marrow transplantation with GvHD. Frontiers in Immunology. 14. 1203614–1203614. 1 indexed citations

Wu, Ying, Qi Chen, Xuying Pei, et al.. (2023). Comparison of Safety and Efficacy between Venetoclax Combined with CAG (cytarabine, aclarubicin, G-CSF) Regimen and CAG Regimen Alone in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood. 142(Supplement 1). 1525–1525. 1 indexed citations

Hu, Guanhua, Yifei Cheng, Ying‐Jun Chang, et al.. (2022). Comparisons of Long-Term Survival and Safety of Haploidentical Hematopoietic Stem Cell Transplantation After CAR-T Cell Therapy or Chemotherapy in Pediatric Patients With First Relapse of B-Cell Acute Lymphoblastic Leukemia Based on MRD-Guided Treatment. Frontiers in Immunology. 13. 915590–915590. 7 indexed citations

10.

Hu, Guanhua, Yifei Cheng, Ying‐Jun Chang, et al.. (2022). Chimeric Antigens Receptor T Cell Therapy Improve the Prognosis of Pediatric Acute Lymphoblastic Leukemia With Persistent/Recurrent Minimal Residual Disease in First Complete Remission. Frontiers in Immunology. 12. 731435–731435. 7 indexed citations

11.

Zuo, Wei, Xingxing Yu, Xuefei Liu, et al.. (2022). The Interaction of HLA-C1/KIR2DL2/L3 Promoted KIR2DL2/L3 Single-Positive/NKG2C-Positive Natural Killer Cell Reconstitution, Raising the Incidence of aGVHD after Hematopoietic Stem Cell Transplantation. Frontiers in Immunology. 13. 814334–814334. 7 indexed citations

12.

Qin, Ya‐Zhen, Xiaohong Liu, Jing Wang, et al.. (2021). PML‐RARA transcript levels at the end of induction therapy are associated with prognosis in non‐high‐risk acute promyelocytic leukaemia with all‐trans retinoic acid plus arsenic in front‐line therapy: long‐term follow‐up of a single‐centre cohort study. British Journal of Haematology. 195(5). 722–730. 3 indexed citations

13.

Wu, Yejun, Hui Liu, Qiaozhu Zeng, et al.. (2021). All-trans retinoic acid plus low-dose rituximab vs low-dose rituximab in corticosteroid-resistant or relapsed ITP. Blood. 139(3). 333–342. 11 indexed citations

14.

Wu, Jin, Hai‐Xia Fu, Xiao‐Dong Mo, et al.. (2021). Risk factors and outcomes of diffuse alveolar haemorrhage after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation. 56(9). 2097–2107. 10 indexed citations

15.

Wang, Xiang, Xingxing Yu, Zeying Fan, et al.. (2021). Donor activating killer cell immunoglobulin‐like receptors genes correlated with Epstein–Barr virus reactivation after haploidentical haematopoietic stem cell transplantation. British Journal of Haematology. 196(4). 1007–1017. 5 indexed citations

16.

He, Hanqing, Panglian Xu, Xiaofei Zhang, et al.. (2020). Aging-induced IL27Ra signaling impairs hematopoietic stem cells. Blood. 136(2). 183–198. 66 indexed citations

17.

Chen, Qi, Xin Zhao, Hai‐Xia Fu, et al.. (2020). Posterior reversible encephalopathy syndrome (PRES) after haploidentical haematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transplantation. 55(10). 2035–2042. 10 indexed citations

18.

Xu, Linlin, Hai‐Xia Fu, Jiamin Zhang, et al.. (2017). Impaired Function of Bone Marrow Mesenchymal Stem Cells from Immune Thrombocytopenia Patients in Inducing Regulatory Dendritic Cell Differentiation Through the Notch-1/Jagged-1 Signaling Pathway. Stem Cells and Development. 26(22). 1648–1661. 36 indexed citations

19.

Zhao, Xiaosu, Ying‐Jun Chang, Lan‐Ping Xu, et al.. (2014). Rapid early recovery of absolute lymphocyte counts at day 30 can predict reduced risk of relapse in acute lymphoblastic leukemia following haploidentcial allogeneic stem cell transplantation. 35(1). 3–7. 1 indexed citations

20.

Lv, Meng, Xiao‐Su Zhao, Xiaosu Zhao, et al.. (2013). Ceruloplasmin Is a Potential Biomarker for aGvHD following Allogeneic Hematopoietic Stem Cell Transplantation. PLoS ONE. 8(3). e58735–e58735. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact